A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-11. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
General sources Johnson-Elie, Tannette (December 5, 2006). "Mixing kindness with business". Milwaukee Journal Sentinel. Archived from the original on September 29, 2007. Naylor, June (February 20, 2004). "Charlie's is hot on the grill (free preview)". Fort Worth Star-Telegram. Chan, Candy Kit Har (November 25, 1994). "Steaking His Claim: Crafty Charley Shin Proves Fast Food, Franchising". AsianWeek. Archived from the original on May 16, 2011 – via HighBeam Research.
Furthermore, apamin has been found to be 1000 times more efficient when applied into the ventricular system instead of the peripheral nervous system. The ventricular system is a set of structures in the brain containing cerebrospinal fluid. The peripheral nervous system contains the nerves and ganglia outside of the brain and spinal cord. This difference in efficiency can easily be explained. Apamin binds to the SK channels, which differ slightly in different tissues. So apamin binding is probably stronger in SK channels in the ventricular system than in other tissues.
=== Miscellaneous methods and compounds === In reductive decyanation the nitrile group is replaced by a proton. Decyanations can be accomplished by dissolving metal reduction (e.g. HMPA and potassium metal in tert-butanol) or by fusion of a nitrile in KOH. Similarly, α-aminonitriles can be decyanated with other reducing agents such as lithium aluminium hydride. In the so-called Franchimont Reaction (developed by the Belgian doctoral student Antoine Paul Nicolas Franchimont (1844-1919) in 1872), an α-cyanocarboxylic acid heated in acid hydrolyzes and decarboxylates to a dimer. Nitriles self-react in presence of base in the Thorpe reaction in a nucleophilic addition In organometallic chemistry nitriles are known to add to alkynes in carbocyanation:
=== Non-volatile chlorogenic acids === Chlorogenic acids belong to a group of compounds known as phenolic acids. The content of chlorogenic acids in dried arabica green coffee beans is 65 mg/g, and in robusta 140 mg/g, depending on the time of harvest. At roasting temperature, more than 70% of chlorogenic acids are destroyed. Chlorogenic acids are homologous compounds comprising caffeic acid, ferulic acid and 3,4-dimethoxycinnamic acid, which are connected by an ester bond to the hydroxyl groups of quinic acid. Chlorogenic acids have a bitter taste in low concentrations such as 50 mg/L water. At higher concentrations of 1 g/L water, they have a sour taste. Chlorogenic acids increase the solubility of caffeine, and are important modulators of taste.
Sources: en.wikipedia.org
Thomas Bellchambers (born 9 July 1989) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). He is a current professional boxer. After playing for the Tasmanian Devils in the TAC Cup, he was drafted with pick 8 in the 2007 pre-season draft. He made his debut against Hawthorn in Round 11 of the 2008 AFL season. He announced his retirement from the AFL on the 15th of September 2020. Bellchambers, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 AFL season. He announced his retirement on 15 September 2020, after 136 games. On 24/05/23 Bellchambers made his professional boxing debut Vs Cameron Mooney in Melbourne, Bellchambers won by KO in the 3rd round. The fight was in the heavyweight division. Bellchambers professional boxing record is 1-0. (1 by KO)
=== Effects on the economy === Beyond its social and political toll, the Mexican drug war has also had significant economic consequences. It has increased costs for businesses, disrupted supply chains, and raised insurance premiums. Small and medium businesses in cartel-dominated areas are affected by widespread extortion, known as piso, while multinational corporations have delayed or reduced investments due to security risks. At the government level, the costs of military deployment and police expansion have represented a growing fiscal burden. Given Mexico's high rates of tax noncompliance, these expenditures have further constrained public finances and limited funding for other essential services. Finance Minister Agustín Carstens said that the deteriorating security alone is reducing gross domestic product annually by 1% in Mexico, Latin America's second-largest economy.
In 2005, the Siuzdak lab was engaged in identifying metabolites associated with sepsis and in an effort to address the issue of statistically identifying the most relevant dysregulated metabolites across hundreds of LC/MS datasets, the first algorithm was developed to allow for the nonlinear alignment of mass spectrometry metabolomics data. Called XCMS, it has since (2012) been developed as an online tool and as of 2019 (with METLIN) has over 30,000 registered users. On 23 January 2007, the Human Metabolome Project, led by David S. Wishart, completed the first draft of the human metabolome, consisting of a database of approximately 2,500 metabolites, 1,200 drugs and 3,500 food components. Similar projects have been underway in several plant species, most notably Medicago truncatula and Arabidopsis thaliana for several years. As late as mid-2010, metabolomics was still considered an "emerging field". Further, it was noted that further progress in the field depended in large part, through addressing otherwise "irresolvable technical challenges", by technical evolution of mass spectrometry instrumentation. In 2015, real-time metabolome profiling was demonstrated for the first time.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.